长链非编码RNA（lncRNA）是一类长度大于200个核苷酸转录本，通过调控DNA、RNA及蛋白质的表达和功能，参与肿瘤发生、发展并发挥重要作用的RNA，近年来lncRNA成为恶性肿瘤早期诊断和预后标志物研究新的关注方向。Linc-UBC1作为一种新发现的lncRNA，在多种恶性肿瘤如肺癌、胃癌、结直肠癌、宫颈癌、卵巢癌、食管鳞癌等中异常高表达，可通过作为竞争性RNA（ceRNA）、参与信号通路等促进肿瘤细胞的增殖、迁移、侵袭、细胞周期进展、细胞凋亡和上皮间充质转化（EMT）等过程；高表达的linc-UBC1能够增加恶性肿瘤的耐药性，其表达水平与肿瘤分期、淋巴结转移和原发肿瘤远处转移呈正相关；linc-UBC1有望成为许多恶性肿瘤的新型的生物标志物、预后预测因子和治疗靶点，但其具体的调控机制仍处于研究的早期阶段，有待进一步深入研究。文章就目前linc-UBC1在恶性肿瘤发生和发展中的作用研究进展进行综述。

       Long non-coding RNA（lncRNA）is a class of transcripts with a length of more than 200 nucleotides．It is 

involved in the occurrence and development of tumors and plays an important role by regulating the expression and function of DNA，RNA and protein．In recent years，lncRNA has become a new research direction for early diagnosis and prognosis of malignant tumors．As a newly discovered lncRNA，linc-UBC1 is abnormally highly expressed in a variety of malignant tumors such as lung cancer，gastric cancer，colorectal cancer，cervical cancer，ovarian cancer，and esophageal squamous cell carcinoma．It can  promote the proliferation，migration，invasion，cell cycle progression，cell apoptosis and EMT of tumor cells by acting as a competing endogenous RNA（ceRNA）and participating in signaling pathways．High expression of linc-UBC1 can increase the drug resistance of malignant tumors，and its expression level is positively correlated with tumor stage，lymph node metastasis and distant metastasis of primary tumors．linc-UBC1 is expected to become a new biomarker，prognostic predictor and therapeutic target for many malignant tumors，while its specific regulatory mechanism is still in the early stage of research and needs further in-depth study．This article reviews the current research progress of linc-UBC1 in the occurrence and development of malignant tumors．

       实体瘤对免疫治疗应答非常有限，因此，如何有效提升肿瘤免疫治疗的疗效，已成为当前肿瘤免疫治疗领域亟待解决的关键难题与挑战。髓系来源抑制性细胞（MDSCs）的趋化募集及其所介导的肿瘤免疫逃逸机制，是制约实体瘤免疫治疗效果的核心因素之一。文章深入探讨了MDSCs的起源、表型特征、其介导肿瘤免疫逃逸的具体机制，以及当前针对MDSCs的靶向治疗策略与将MDSCs靶向疗法与肿瘤免疫治疗相结合的最新研究进展。此外，文章还系统性地分析了靶向MDSCs联合免疫治疗策略所面临的关键挑战，并据此提出了MDSCs的精准靶向策略。这一策略旨在精确激活抗肿瘤免疫反应，为癌症患者提供更为个性化、高效的治疗方案，从而开启肿瘤免疫治疗领域的新纪元，为癌症治疗策略的创新与发展贡献力量。

  Solid tumors exhibit a very limited response to immunotherapy．Consequently，effectively enhancing the therapeutic efficacy of tumor immunotherapy has emerged as a critical challenge and problem that urgently needs to be addressed in tumor immunotherapy．The chemotaxis and recruitment of myeloid-derived suppressor cells（MDSCs）and the tumor immune evasionmechanisms mediated by them are one of the core factors that significantly restrict the efficacy of immunotherapy for solid tumors．In this review，we discuss the origins and phenotypic characteristics of MDSCs，the specific mechanisms by which they mediate tumor immune evasion，as well as current targeted therapeuticstrategies for MDSCs and the latest research progress in combining MDSC-targeted therapy with tumor immunotherapy．Furthermore，we  have  systematically analyzed the  key challenges faced by the combination of MDSC-targeted and immunotherapy strategies，and accordingly proposed a precise targeting strategyfor MDSCs．This strategy aims to precisely activate anti-tumor immune responses，providing more personalized and efficienttreatment options for cancer patients，thereby opening a new era in tumor immunotherapy and contributing to the innovation anddevelopment of cancer treatment strategies．

乳酸以往被视为不具备生物学功能的代谢废物。随着人们对乳酸的深入研究,发现乳酸有多种作用。乳酸化修饰是近期发现一种与乳酸有关的蛋白质翻译后修饰过程。乳酸化修饰主要有两种,一种是与乳酸相关的直接修饰,另外一种是与丙酮酸相关的间接修饰。这两种乳酸化修饰均可能受到糖酵解、乳酸转运与堆积、蛋白质串扰以及神经系统等多方面的调控。乳酸化修饰可以通过直接或间接修饰组蛋白或非组蛋白,从而在肿瘤组织的代谢重编程、增殖、迁移及免疫逃逸中发挥着重要作用。乳酸化修饰的深入研究,有望为肿瘤的诊断和治疗开辟新的路径。因此,为了明确乳酸化修饰在肿瘤方面的研究进展,本文就蛋白乳酸化修饰的分子机制及其在肿瘤中作用的研究进展作一综述。

       Lactic acid was previously regarded as a metabolic waste product with no biological function. As lactic acid has been intensively studied, it has been found to have multiple roles. Lactation modification is a recently discovered protein post-translational modification process related to lactic acid. There are two main types of lactation modification：one is direct modification related to lactic acid and the other is indirect modification related to pyruvate. Both types of lactation modification may be regulated by various aspects such as glycolysis, lactate transport and accumulation, protein crosstalk, and the nervous system. Lactation modification can play an important role in metabolic reprogramming, proliferation, migration, and immune escape of tumor tissues by directly or indirectly modifying histones or non-histone proteins. The in-depth study of lactation modification is expected to find new pathways for tumor diagnosis and treatment. Therefore, in order to clarify the research progress of lactation modification in tumors, this paper presents a review on the molecular mechanism of protein lactation modification and the research progress of its role in tumors.